Terry T. Takahashi

Terry T. Takahashi

Auto-generated profile, based on publicly available information

Terry T. Takahashi

Department of Chemistry, University of Southern California, Los Angeles, CA, 90089, USA.

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
GKGolnaz Kamalinia
Golnaz Kamalinia
BGBrian J. Grindel
Brian J. Grindel
TTTerry T. Takahashi
Terry T. Takahashi
SMSteven Wesley Millward
Steven Wesley Millward
RRRichard W. Roberts
Richard W. Roberts
In this review, Kamalinia et al. discuss mRNA display and its role in peptide and protein design.

15 March 2021 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
ABAaron T. Balana
Aaron T. Balana
PLPaul M. Levine
Paul M. Levine
TCTimothy W. Craven
Timothy W. Craven
SMSomnath Mukherjee
Somnath Mukherjee
NPNichole J. Pedowitz
Nichole J. Pedowitz
MPMatthew Pratt
Matthew Pratt

30 April 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
GKGolnaz Kamalinia
Golnaz Kamalinia
BEBrian J. Engel
Brian J. Engel
ASAnupallavi Srinivasamani
Anupallavi Srinivasamani
BGBrian J. Grindel
Brian J. Grindel
JOJustin N. Ong
Justin N. Ong
RRRichard W. Roberts
Richard W. Roberts

25 August 2025 in Protein Science
Verified
Journal Article
Open access
JOJustin N. Ong
Justin N. Ong
BGBrian J. Grindel
Brian J. Grindel
SRScott A. Rankin
Scott A. Rankin
SNSarah H. Naylon
Sarah H. Naylon
ASAnupallavi Srinivasamani
Anupallavi Srinivasamani
SMSteven Wesley Millward
Steven Wesley Millward
Many peptide drugs rely on nonproteinogenic amino acids and chemical modifications for improved activity and proteolytic stability. However, these features also make drug production expensive and challenging to scale. Here, we engineered small, linear, proteinogenic peptides that bind human programmed death‐ligand 1 (hPD‐L1) with high affinity and stability using mRNA display affinity maturation. The resulting peptides, SPAM2 and SPAM3, have antibody‐like affinities for hPD‐L1 (dissociation constants between ~250 and 300 pM) and are selective for hPD‐L1. Both SPAM2 and SPAM3 compete with hPD‐L1 ligands known to interact with the programmed cell death protein 1 site and are stable in human serum. SPAM3 bound human glioma D423 cells with high affinity in flow cytometry experiments comparable to that of a clinical therapeutic antibody. These results support the use of affinity maturation selections to dramatically enhance the biophysical properties of linear, proteinogenic peptides for translational applications.

28 October 2025 in ChemBioChem
Verified
Journal Article
Open access
PQPearl Qi
Pearl Qi
YGYash Pragnesh Gandhi
Yash Pragnesh Gandhi
KZKexin Zheng
Kexin Zheng
FJFarzad Jalali‐Yazdi
Farzad Jalali‐Yazdi
JOJustin N. Ong
Justin N. Ong
RRRichard W. Roberts
Richard W. Roberts
In vitro directed evolution techniques, such as mRNA display, enable peptide ligand discovery and optimization. However, physical libraries that rely on a genetic code can only search a small fraction of sequence space due to inherent biases in the genetic code and experimental limitations. To address this challenge, denoising diffusion implicit models (DDIMs) are applied to generate novel peptide ligands against B‐cell lymphoma extra‐large (Bcl‐x L ), a key cancer target. Starting with high‐throughput sequencing data from previous selections, a DDIM is trained to produce novel sequences with high affinity binding. Experimental validation confirms that most generated sequences are functionally equivalent to the original library members for Bcl‐x L binding and demonstrated comparable binding kinetics and affinity relative to the wildtype and nearest original neighbors. Importantly, this approach generated rare sequences not easily accessible via mutation and directed evolution. These results indicate that DDIMs can complement and expand directed evolution data, efficiently exploring underrepresented regions of sequence space. This approach provides a broadly applicable framework for accelerating ligand discovery and optimizing molecular properties across diverse targets.

10 December 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAaron T. Balana
Aaron T. Balana
PLPaul M. Levine
Paul M. Levine
SMSomnath Mukherjee
Somnath Mukherjee
NPNichole J. Pedowitz
Nichole J. Pedowitz
SMStuart P. Moon
Stuart P. Moon
MPMatthew Pratt
Matthew Pratt
A major role for the intracellular posttranslational modification O-GlcNAc appears to be the inhibition of protein aggregation. Most of the previous studies in this area have focused on O-GlcNAcylation of the amyloid-forming proteins themselves. Here, we use synthetic protein chemistry to discover that O-GlcNAc also activates the anti-amyloid activity of certain small heat shock proteins (sHSPs), a potentially more important modification event that can act broadly and substoichiometrically. More specifically, we find that O-GlcNAcylation increases the ability of sHSPs to block the amyloid formation of both α-synuclein and Aβ. Mechanistically, we show that O-GlcNAc near the sHSP IXI-domain prevents its ability to intramolecularly compete with substrate binding. Our results have important implications for neurodegenerative diseases associated with amyloid formation and potentially other areas of sHSP biology.